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Abstract
Background: Inflammation is commonly associated with lung tumors. Since inflammatory mediators, including
members of the interleukin-6 (IL-6) cytokine family, suppress proliferation of normal epithelial cells, we
hypothesized that epithelial cells must develop mechanisms to evade this inhibition during the tumorigenesis. This
study compared the cytokine responses of normal epithelial cells to that of premalignant cells.
Methods: Short-term primary cultures of epithelial cells were established from bronchial brushings. Paired sets
of brushings were obtained from areas of normal bronchial epithelium and from areas of metaplastic or dysplastic
epithelium, or areas of frank endobronchial carcinoma. In 43 paired cultures, the signalling through the signal
transducer and activator of transcription (STAT) and extracellular regulated kinase (ERK) pathways and growth
regulation by IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM), interferon-γ (IFNγ) or epidermal growth
factor (EGF) were determined. Inducible expression and function of the leukemia inhibitory factor receptor was
assessed by treatment with the histone deacetylase inhibitor depsipeptide.
Results: Normal epithelial cells respond strongly to OSM, IFNγ and EGF, and respond moderately to IL-6, and
do not exhibit a detectable response to LIF. In preneoplastic cells, the aberrant signaling that was detected most
frequently was an elevated activation of ERK, a reduced or increased IL-6 and EGF response, and an increased LIF
response. Some of these changes in preneoplastic cell signaling approach those observed in established lung
cancer cell lines. Epigenetic control of LIF receptor expression by histone acetylation can account for the gain of
LIF responsiveness. OSM and macrophage-derived cytokines suppressed proliferation of normal epithelial cells,
but reduced inhibition or even stimulated proliferation was noted for preneoplastic cells. These alterations likely
contribute to the supporting effects that inflammation has on lung tumor progression.
Conclusion: This study indicates that during the earliest stage of premalignant transformation, a modified
response to cytokines and EGF is evident. Some of the altered cytokine responses in primary premalignant cells
are comparable to those seen in established lung cancer cell lines.
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Background
Lung epithelial cells are consistently exposed to many irri-
tants and pathogens. Excessive exposure can lead to
inflammatory conditions even though effective mecha-
nisms are in place to contain and remove harmful compo-
nents [1]. Epithelial damage results in tissue repair.
Chronic injury and repeated cycles of tissue repair in pres-
ence of an inflammatory reaction may provide conditions
that are conducive for selection of cells with enhanced
proliferation and/or reduced sensitivity to signals for
growth arrest and differentiation [2]. An environment that
favors tumorigenesis is created when genetic and epige-
netic changes enhance proliferation, reduce differentia-
tion and/or attenuate apoptotic reactions [3]. Changes in
epithelial morphology and proliferation may result in
decreased autofluorescence that is grossly detectable with
autofluorescence bronchoscopy [4]. A step-wise progres-
sion has been hypothesized to precede frank malignancy
[5,6], and recent autofluorescence bronchoscopy studies
have confirmed the malignant potential of metaplasia
and dysplasia of the bronchial epithelium [7-9]. Direct
visualization of these changes has made it possible to bet-
ter understand the role of inflammation in lung carcino-
genesis.
Inflammation has been reported to contribute to the
development of cancer [1,2,10,11], and IL-6 cytokines,
such as oncostatin M (OSM), actually arrest growth of cul-
tured epithelial [12] and other cell types [13]. We hypoth-
esized that members of the interleukin-6 (IL-6) cytokine
family may contribute to the step-wise progression by
providing growth-stimulatory activity. We also hypothe-
sized that the transformed premalignant cells escape the
inhibitory activity of cytokines as a function of the trans-
formation process and that these transformed cells have
altered cytokine responsiveness. These alterations should
include reduced signaling through growth-suppressing
pathways and/or enhanced signaling through growth-pro-
moting pathways.
IL-6 cytokines are recognized by receptors that belong to
the group of hematopoietin receptors [14]. Signal trans-
duction is communicated by receptor-associated Janus
protein tyrosine kinases that phosphorylate the receptor
subunits. The signaling proteins are recruited to the tyro-
sine phosphorylated receptors, include signal transducer
and activator of transcription-3 (STAT3), the protein tyro-
sine phosphatase SHP-2 and the adaptor Shc, which link
to the RAS-MAPK-ERK pathway [14,15]. The magnitude
of these immediate signaling reactions is a measure for the
level of receptor activation in treated cells, and this is par-
ticularly true for the tyrosine phosphorylation of STAT3
and dual phosphorylation of ERK1/2 [16].
At the present time, very little is known about: (a) the
response pattern of normal, non-immortalized human
lung epithelial cells to inflammatory mediators, (b) the
individual variation of the response patterns, and (c) the
effects that premalignant transformation has on the
responsiveness. Our study was designed to determine the
response of bronchial epithelial cells from normal epithe-
lium and abnormal lesions to inflammatory mediators
and IL-6-type cytokines, and to define the effects of these
cytokines on signaling and cell growth regulation. We
developed techniques for obtaining proliferating epithe-
lial cell cultures from bronchoscopy brushings and we
used those cultures for functional screening.
Methods
Patient population
Patients with tobacco exposure who were enrolled in an
institutional lung cancer screening trial underwent
autofluorescence bronchoscopy using the LIFE system
(LIFE systems, Xillix, Vancouver BC) in concert with low-
dose spiral CT of the chest [17]. Informed consent was
obtained and procedures were performed in accordance
with an IRB-approved protocol.
Bronchoscopy and cytologic brushing
Bronchoscopy was performed under monitored anesthe-
sia care. The airways were examined with white light and
for autofluorescence. The appearance of the bronchial
mucosa was classified as normal or abnormal. Bronchial
epithelial brushings (area of ~25 mm2) and biopsies were
taken from one normal and one to three abnormal sites.
Cytology samples from the brushings were directly
smeared onto glass slides and fixed in 95% ethanol. Resid-
ual tissue on the cytology brush was then used to establish
cell cultures. Diagnoses of metaplasia, grades of dysplasia
or non-invasive carcinoma in situ were made strictly
based on the criteria established by the World Health
Organization [18].
Primary epithelial cell cultures from bronchial brushing
The cytology brush with adherent tissue was incubated in
5 ml of trypsin (1/125 dilution in PBS; Invitrogen,
Carlsbad, CA) at 37°C for 5 min. Dissociated cells were
collected by centrifugation, resuspended in serum- and
calcium-free keratinocyte medium containing human
recombinant EGF, bovine pituitary extract, cholera toxin,
and mycostatin (Invitrogen), and plated into one 3.5-cm
diameter, collagen type-1-coated dish. The number of
adherent cells after 24 h incubation ranged from <1 to ~20
× 103. Medium was replaced every 4 days. When success-
ful (generally with >5 × 103 cells initially present), prolif-
erating epithelial cells reached 80% confluence (~1 × 106
cells) in 2–3 weeks. Subcultures of the first passage (in 24-
well culture plate) were used to determine the cytokine
response patterns and cellular homogeneity by immunos-BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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taining for expression of cytokeratin (class AE1/3 pancy-
tokeratin). Cultures from the second passage were used
for thymidine incorporation. Cells from the third passage
were used for confirming consistency of cytokine response
profile and spectral karyotyping (SKY) [19]. Of note is
that all primary epithelial cultures showed limited life
span and ceased to divide after 4 to 7 passages.
Isolation of macrophages, fibroblasts, and type II epithelial 
cells
Human residual lung tissue was obtained from Roswell
Park Cancer Institute Tissue Procurement Service under an
IRB-approved protocol. Macrophages were mechanically
extracted from minced lung tissue, purified by Histopaque
gradient centrifugation (Sigma Chemical Co., St. Louis,
MO) and plated at a density of 3 × 105 cells/cm2 in RPMI-
1640 containing 10% FCS. After 45 min, adherent cells
(>95% macrophages) were incubated in medium (1 ml/1
× 106 cells) containing 1 µg/ml LPS. Conditioned medium
was collected after 16 h. The concentrations of cytokines
were determined by multiplex immunobead flow cytom-
etry (Luminex Inc., Austin, TX). To obtain fibroblasts,
macrophage-depleted lung tissue pieces were incubated
with RPMI-1640 containing 10% FCS, antibiotics and
mycostatin. After 7–10 days, fibroblasts had grown out of
the pieces to ~50% confluence. These were selectively
released by digestion with trypsin for 2–5 min at room
temperature. Fibroblasts from passage 2 were used for
analysis. To obtain type II epithelial cells, macrophage-
depleted residual lung tissue pieces were incubated with 5
volumes of trypsin for 15 min at 37°C. Trypsin digestion
was repeated. Cells released during the second digestion
were cultured as described for bronchial epithelial cells.
The homogeneity of epithelial cell population was deter-
mined by immunostaining of first passage cultures for
surfactant expression (Dako, Captine, CA) [20].
Established lung cell lines
Bronchial epithelial cell lines immortalized with the
human papilloma virus E6E7 gene, HBE4 and HBE137
(ATCC, Manassas, VA), were cultured like primary bron-
chial epithelial cells. The non-small cell lung cancer cell
line A549 was grown in DMEM containing 10% FCS, and
the NCI lines H23, H125, H358, H441, H522 (ATCC)
and ADLC [21] were cultured in RPMI-1640 medium con-
taining 10% FCS.
Cytokine treatments for analysis of signalling
Cells were seeded into 24-well plates. When the cultures
reached ~90% confluence, they were incubated for 2 h in
serum- and factor-free RPMI-1640 (to reduce signalling
effects by serum growth factors or EGF), followed by treat-
ment for 15 min with the same medium containing 100
ng/ml recombinant IL-6, OSM (Amgen Corporation, Seat-
tle, WA), LIF (Wyeth Pharmaceuticals, Cambridge MA),
EGF (Gibco-Invitrogen Carlsbad, CA), 100 units/ml IFNγ
(Roche Applied Science, Indianapolis, IN), 500 ng/ml
insulin or 0.1 µM phorbol myristic acid (Sigma, St. Louis,
MO). Cells were washed with PBS and lysed with RIPA
buffer containing 0.1 mM orthovanadate and 1:100
diluted protease inhibitor cocktail (Calbiochem, San
Diego, CA). LIF receptor (LIFR) expression was induced
by treating epithelial cells with growth medium contain-
ing 20 nM of the histone deacetylase inhibitor depsipep-
tide FR901228 (NCI) [22].
Growth analysis
Cells were seeded at 5% confluence (~1–5 × 103 primary
epithelial cells, HBE135 and fibroblasts) or 1% conflu-
ence (~0.5–4 × 103 cells from established lines) into 24-
well culture plates using the appropriate complete growth
medium. Replicate cultures were treated with complete
growth medium containing serially diluted cytokines or
conditioned medium of LPS-activated macrophages. At
day 3, the media were replaced and at day 6, the cells were
released by trypsin digestion and the number of viable
(trypan blue dye-excluding) cells counted in a hemocy-
tometer. In each series, the mean number of cells recov-
ered for cultures treated with growth medium alone
(ranged from 0.5 to 4 × 105) was used as used as internal
reference (defined as 100%).
Thymidine incorporation
Epithelial cells were seeded with growth medium into 24-
well culture plates (~5 × 104 cells per well). After 24 h,
duplicate cultures were treated with growth medium con-
taining serially diluted OSM or conditioned medium
from LPS-activated macrophages. Twenty-four hours later,
1  µCi of [3H]thymidine (Amersham Biosciences) was
added to each culture and incubation of the cells contin-
ued for an additional 16 h. Cells were released by trypsin
and collected onto filter paper by a cell harvester (Tomtec,
Hamden, CT). The amount of incorporated tritium was
measured by a scintillation counter (Trilux microbeta,
Turku Finland). The mean of the net values of the dupli-
cate wells was expressed relative to the mean incorpora-
tion determined for the control cultures in each of the
series, which was defined as 100%.
Western blot analysis
Replicate aliquots of cell lysates, containing 10 µg of pro-
tein, were electrophoresed on 7.5% polyacrylamide gels
[16]. Extracts from paired samples were co-analyzed. The
proteins were transferred to protean membranes (Sch-
leicher & Schuell, Keene, NH). Immediately after transfer,
the membranes were stained with Ponceau red to verify
equal loading and membrane-transfer of proteins. In each
experimental series, two replicate blots were horizontally
cut at the ~60 kD size position; the upper sections were
used to probe for phosphorylated and total STAT3 and theBMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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Cytokine response of lung cells Figure 1
Cytokine response of lung cells. A. Primary cultures of the normal type II epithelial cells and fibroblasts from residual lung 
tissue and the indicated cell lines were treated for 15 min with factors listed at the bottom. Extracts were analyzed by immu-
noblotting for phosphorylated STAT3 and ERK-1/-2. The level of immunodetectable total ERK-1/-2 indicates protein loading. 
B. The quantitative values (mean and SD) for the phosphorylation of ERK-1/-2 (open bars) and STAT3 (closed bars) by treat-
ments with LIF, OSM, IL-6 and EGF were determined in 5 independent experiments (expressed relative to the OSM effect, 
equal 100%). C. Extracts from control treated cultures from A were analyzed for the immunodetectable level of total STAT3 
and ERK-1/-2. D. Type II epithelial cells were treated for the indicated length of time with OSM (100 ng/ml) and the level of 
phosphorylated STAT3 and ERK-1/-2 was determined by immunoblotting.BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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lower sections for phosphorylated ERK and total ERK.
Separate blots were used to probe for phosphorylated and
total STAT1. In cases where larger higher amounts of cells
were recovered, extracts were also analyzed for receptor
proteins. The membranes were reacted with antibodies to
phospho-specific forms or ERK1/2, STAT1, STAT3 and
EGFR (Cell Signalling Technology, Inc., Beverly, MA) and
total forms of ERK1/2, STAT1, and STAT3, LIFR (Santa
Cruz, Santa Cruz, CA). The membranes were incubated
with the appropriate peroxidase-conjugated secondary
antibodies (ICN Biomedical, Aurora, OH) and the anti-
body binding was visualized by enhanced chemilumines-
cence reaction (Amersham Biosciences Piscataway, NJ). In
each experimental series, immunoblots were exposed to
X-ray films for various lengths of time (1 sec to 30 min) to
obtain images that are in the linear range of signal detec-
tion [23]. For pictorial presentation of immunoblot data,
the signals for either total STAT3 or ERK1/2 served as load-
ing controls.
Densitometric analysis
Immunoblots were digitalized and quantified with Image
Quant TL Software (Amersham Biosciences Piscataway,
NJ). The net pixel value for each protein band that lied
within the linear range of detection was normalized to the
co-analyzed standard. To compare the responses between
normal and abnormal epithelial cell cultures from indi-
vidual donors, as well the responses among different
donors, the OSM-induced phosphorylation of STAT1,
STAT3 and ERK1/2 in the normal cell cultures of each
paired set was used as an internal reference (defined as
100). Similarly, the magnitude of increased or decreased
signalling in cells from paired cultures was defined by the
ratio with the values obtained for the cells derived from
the bronchial sites initially identified as being normal.
Since the level of phosphorylated STAT3 in LIF-treated
normal cells was generally undetectable, we arbitrarily
used 1% as lowest value for calculating fold changes.
Thus, the calculated values for LIF effects may represent
underestimates. Basal levels of signalling and cytokine
responses of cell lines were determined by the level of
phosphorylated STAT3 and ERK1/2 and normalized to
that values obtained for the same cells treated with OSM
(defined as 100%).
Statistical evaluation
The inferences for all the hypothesis tests are based on the
significance level of 0.05. All statistical analyses were per-
formed in an exploratory manner. For each combination
of biomarker (P-STAT1, P-STAT3, and P-ERK) and treat-
ment (one control and 5 cytokines), the relative increase
in phosphorylation in the abnormal cells compared with
its matched normal cells from the same patient was sub-
jected to the exact sign test with paired samples. A
decrease or increase of DNA syntheses within a treatment
(OSM or macrophage factors) by different doses of the
treatment was tested using the exact sign test with paired
samples and the exact Page's L test. The DNA synthesis val-
ues of normal and metaplastic cell cultures in paired sam-
ples were compared using the exact Wilcoxon two-sample
test.
Results
Transformed lung epithelial cell lines have grossly 
abnormal patterns of cytokine responsiveness
We predicted that if oncogenic transformation of lung epi-
thelial cells is associated with altered responsiveness to
inflammation and reduced growth-inhibition, then the
most prominent deviations from the regulatory pheno-
type should be seen in advanced lung cancer cells. There-
fore, as first step, we determined if responsiveness to
members of the IL-6 family (IL-6, OSM and LIF) were
detectable in established lines of malignant human non-
small cell lung carcinoma cells. The responsiveness to the
cytokines was defined by measurable phosphorylation of
STAT and ERK. This is a treatment reaction that is a meas-
ure for the level of active cytokine receptors and down-
stream signaling pathways in the target cells [14,16].
Normal type II epithelial cells and pulmonary fibroblasts
were included in the analyses to gauge cell type-specific
differences in signaling reactions (Fig. 1).
Phosphorylation of STAT3 and ERK was sufficient for
identifying responsiveness to cytokines in specific cell
types (Fig. 1A shows representative immunoblots and Fig.
1B presents the quantitative data from independently per-
formed experiments involving 5 separate matched cul-
tures of type II epithelial cells and fibroblasts). In brief,
normal type II epithelial cells showed the following fea-
tures (Fig. 1A, top panel): OSM strongly activated phos-
phorylation of STAT3 and ERK, while IL-6 was less
effective, and LIF did not produce any detectable
response. EGF stimulated phosphorylation of ERK in the
range of OSM, while insulin was minimally effective.
Fibroblasts exhibited a prominent LIF response and a sev-
eral-fold higher activation of ERK relative to STAT3 by IL-
6 cytokines (Fig. 1A, bottom panel), in contrast to normal
epithelial cells. The maximal level of receptor action in
epithelial cells was reached after 15 min agonist treatment
(Fig. 1D, example of OSM on normal type II epithelial
cells).
Deviations from the normal regulatory phenotype of epi-
thelial cells were already evident in immortalized bron-
chial epithelial cells, HBE4 (Fig. 1A) and HBE137 (not
shown). These cell lines responded to IL-6 cytokines like
normal epithelial cells, but showed a detectable STAT3
signaling by LIF and a ~2-fold higher ERK activation by
OSM and IL-6. More profound differences were detected
in carcinoma lines (Fig. 1A and not shown). In carcinomaBMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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cell lines, the major trends included a strong STAT3 acti-
vation by LIF (ADLC, H125), an increased (ADLC, H23)
or decreased STAT3 activation by IL-6 (H125, H324), a
decreased ERK activation by EGF (H522), and a treat-
ment-independent, constitutive activation of the ERK
pathway (H23). Despite the substantial changes in
response patterns, STAT and ERK signaling in response to
OSM was consistently high in all analyzed lung cancer cell
lines. Moreover, the cell-type and line specific differences
in STAT3 and ERK signaling were not due different expres-
sion of the signaling proteins as demonstrated by the
comparable expression level of total STAT3 and ERK pro-
teins among the cell types (Fig. 1C).
Cell line-specific effect of cytokines on proliferation
To relate cytokine signaling with effects on cell prolifera-
tion, representative lung cell types were cultured for 6 days
in growth medium containing in addition increasing con-
centrations of OSM, IL-6 or LIF (Fig. 2). In all cell types,
OSM reduced in a dose-dependent manner proliferation,
with maximal effect at a concentration of 20 to 100 ng/ml.
Maximal inhibition varied among the cell types and
ranged from >80% (normal primary epithelial cells) to
~40% (HBE137, A549, fibroblasts) and ~20% (H23). IL-
6 and LIF did not appreciably alter proliferation of epithe-
lial or fibroblastic cells. The comparative analyses also
indicated that immortalization of epithelial cells with the
E6E7 gene (HBE4 or HBE137) or constitutive activation of
ERK pathway (H23) correlated with a lower growth inhi-
bition by OSM.
The same cells were tested for growth in the presence of
conditioned medium from lipopolysaccaride (LPS) acti-
vated macrophages. Such medium is considered to con-
tain a physiologically relevant mixture of inflammatory
mediators (Table 1). The LPS macrophage medium sup-
pressed the proliferation of epithelial cells in a dose-
dependent fashion (Fig. 2). Suppression ranged from
>80% (primary epithelial cells and A549) to <20% in
HBE137 and H23. In contrast, the same treatment led to
enhanced proliferation of fibroblasts.
Taken together, these data indicated that cytokine respon-
siveness and growth regulation by OSM and inflamma-
tory mediators are indeed subject to alterations in lung
epithelial cells in part as a function of immortalization
and transformation. Characteristic changes in the cellular
response patterns may serve as markers for the transfor-
mation process or may even contribute functionally to
tumorigenesis. One of the key questions is at what stage in
the transformation of lung epithelial cells are these
changes established. To address this question, we used
short-term primary cultures of non-immortalized epithe-
lial cells derived from normal and pathologically distinct
stages of premalignant lesions sampled by brushing dur-
ing bronchoscopy of patients. The experimental approach
also allowed us to establish the more basic information of
what is the cytokine responsiveness of normal epithelial
cells and what is the range among individuals.
Application of primary epithelial cells derived from 
bronchial brushing
Epithelial cell cultures were established from the brushed
bronchial epithelium. Biopsies of the same sites were
processed for pathological and cytological evaluation. The
pathological findings (normal, metaplasia, dysplasia or
Effect of cytokines on growth of lung cell cultures Figure 2
Effect of cytokines on growth of lung cell cultures. The cells listed at the top were cultured for 6 days in the presence of 
serially diluted cytokines or conditioned medium of LPS-activated macrophages (CM MΦ). Dilution 1 for the cytokines was 100 
ng/ml and for macrophage medium a 1/10-dilution of the original conditioned medium. The number of viable cells for each cul-
ture was expressed relative to the cell number in the control culture (defined as 100%). Values represent means and S.D. of 4 
separate cultures.
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non-invasive carcinoma in situ) were subsequently
applied in the interpretation of the signaling data (Table
2). No cases of invasive carcinoma or advanced lung can-
cer were included. From May 2000 to March 2005, 192
separate brushings were taken from 96 patients (EC-1 to
EC-96). From these, 113 brushings (59%) yielded suffi-
cient epithelial cells that expanded to cultures suitable for
functional analyses. Approximately 50% of sites initially
judged to be abnormal by bronchoscopy proved to be
normal by histology.
Based on immunostaining, every cell preparation con-
sisted of >95% cytokeratin-positive epithelial cells. All
cultures derived from normal and abnormal sites showed
essentially the same epithelial cell morphology. To deter-
mine whether or not the primary cultures demonstrated
any gross chromosomal abnormalities, cells were ana-
lyzed by SKY. With the exception of one carcinoma, the
cells showed normal karyotypes. The carcinoma cell cul-
ture carried a chromosome 10 deletion (q11.2-q22) in all
metaphase spreads.
Paired epithelial cell cultures indicate the occurrence of 
altered cytokine responsiveness at early stage of 
transformation
The cytokine responsiveness of the epithelial cells was
determined by the activation of signaling and by the effect
on DNA synthesis. Signaling was measured in first passage
subcultures by treatment with cytokines and growth fac-
tors for 15 min followed by immunodetection of the
phosphorylated signaling proteins (representative exam-
ple in Fig. 3). The level of phosphorylated STAT1, STAT3
and ERK1/2 were quantified and expressed relative to the
level of these proteins in OSM-treated normal cultures in
each pair (Fig. 4A–F).
The analyses of normal bronchial epithelial cells defined
the following response pattern. The reaction to cytokine
treatment (Fig. 3) was comparable to that of type II epi-
thelial cells (Fig. 1A). Data from 63 separate preparations
of normal bronchial epithelial cell cultures indicated that
basal level of phosphorylated ERK was consistently low
(7.5 ± 5.6 % of OSM level; mean ± SD) and the basal lev-
els of phosphorylated STAT3 and STAT1 were generally
low to non-detectable. OSM prominently activated ERK
(Fig. 4A &4B) and STAT3 (Fig. 4C &4D). The response was
uniformly high among cultures from different individu-
als. IL-6 response, although quite variable among individ-
uals, was consistently below that of OSM. The level of
activated ERK was 37 ± 18% of OSM (Fig. 4A &4B) and
activated STAT3 was 63 ± + 27% (Fig. 4C &4D). The two-
fold lower activation of ERK relative to STAT3 by IL-6 is
due to the difference in signaling by the IL-6 and OSM
receptor [16,22]. LIF did not elicit a measurable ERK and
STAT3 signaling in any of normal epithelial cell culture.
EGF activated ERK to 90 ± 29% of OSM level (Fig. 4A
&4B). EGF generally had no measurable effect on STAT3
even when the cells were treated with EGF for longer than
15 minutes (not shown). In all cases, IFNγ did not appre-
ciably activate ERK and STAT3, but yielded highest level of
STAT1 phosphorylation (2441 ± 2073% of OSM level
(Fig. 4E &4F). The IFNγ response from patient to patient
showed the highest variability among the cytokine
responses, even though paired cultures from individual
patients exhibited highly consistent levels of STAT1 activa-
tion by IFNγ.
The reproducibility of detecting comparable patterns in
independently derived cell cultures was assessed in those
paired cultures in which the samples were initially classi-
fied as "abnormal" (or "suspicious") by autofluorescence
bronchoscopy but proved normal by subsequent patho-
logical analysis (Fig. 4A,C &4E). When cell cultures were
derived from histologically normal areas with abnormal
fluorescence, the level and range of signaling reactions
elicited by the treatments were essentially identical to
Table 2: Cultures of bronchial epithelial cells used in this study
Number Successful
Patients 96
Brushings (total) 192 113
Paired brushings 89 43
Paired cultures
Normal/Normal 20
Normal/Metaplasia 17
Normal/Dysplasia 2
Normal/Carcinoma 4
Single cultures
Normal 20
Metaplasia 2
Dysplasia 1
Carcinoma 4
Table 1: Cytokine production of pulmonary macrophages
Cytokine Concentration (ng/ml)*
Minus LPS Plus LPS
IL-1β 0.01 ± 0.01 5.4 ± 1.3
TNFα 0.4 ± 0.3 137 ± 44
IL-6 2.0 ± 0.6 290 ± 113
OSM 0.08 ± 0.01 0.87 ± 0.29
IL-8 27 ± 1 101 ± 26
IL-10 0.16 ± 0.01 8.4 ± 1.5
G-CSF 0.09 ± 0.01 20.3 ± 1.6
IL-12 0.01 ± 0.01 0.18 ± 0.03
TGFβ1 < 0.002 < 0.002
* 2 × 106 macrophages/ml incubated for 16 h with medium containing 
1 µg/ml LPS. Mean and S.D., N = 3.BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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those with normal histology and normal fluorescence.
ERK activation by OSM was 108 ± 35%, by IL-6 was 31 ±
15%, and by EGF was 85 ± 40%. STAT3 activation by OSM
was 97 ± 31% and by IL-6 was 63 ± 27%. The cytokine-
induced activation of ERK and STAT3 in paired cultures
indicated highly consistent response patterns (Fig. 4G and
4H, left side panels). Confirmed premalignant epithelial
cells (metaplasia, dysplasia and carcinoma) exhibited two
recurring aberrant phenotypes when compared with nor-
mal cells. The first aberrancy was the elevated basal or
cytokine-stimulated level of phosphorylated ERK (Fig. 4B
and 4G, right panel) and the second was the reactivation
of LIFR function (Fig. 4D and 4H, right panel).
In the 23 preneoplastic cell cultures, the basal level of
phosphorylated ERK was increased to 22 ± 27% of the
OSM value (p = 0.07). Based on two-sample Kolmogorov-
Smirnov test, two cases that were cultured from metaplas-
tic foci were above the 95% confidence interval. Preneo-
plastic cells showed also an overall trend of increased ERK
signaling when treated with OSM (133 ± 66%; p = 0.17)
or IL-6 (53 ± 38%; p = 0.01) but not with EGF (85 ± 67%;
p = 0.46). The ERK signaling by IL-6 and EGF included
several cases that lie outside of the 95% confidence inter-
val. For the IL-6 response, 3/23 cases were above and 5/23
cases below the 95% confidence interval, and for EGF
response, 4/23 cases were above and 3/23 cases below.
STAT3 phosphorylation by OSM and IL-6, and STAT1
phosphorylation by OSM, IL-6 and IFNγ did not show sig-
nificant differences among the cases tested (Fig. 4C–F), in
contrast to ERK phosphorylation.
Among the abnormal epithelial cells with elevated basal
ERK phosphorylation (Fig. 4B), the two cell cultures from
metaplastic foci in the airway were distinct because the
basal ERK phosphorylation that was equivalent to the
OSM-treated control culture (Fig. 5A). The increased
phosphorylation of ERK, but not of STATs in these meta-
plastic cells was similar to the regulatory phenotype of
NCI H23 tumor cell line (Fig. 1A). Due to the elevated
ERK phosphorylation, the response to EGF was obscured,
even though a normal or even enhanced level of EGFR
could be demonstrated (Fig. 5B). The high basal level
phosphorylation of ERK was abrogated by treatment with
U0126, an inhibitor for MEK1 (Fig. 5C), suggesting a con-
stitutive activation of the MAPK pathway upstream of ERK
in these metaplastic cells.
The pair-wise comparison also revealed that 5/23 of the
abnormal cases (4 metaplasia and 1 carcinoma) had a LIF
response detectable by the activation of ERK and STAT3
(Fig. 3, Fig. 4B,D,G and 4H). Three cases (2 metaplasia
and 1 carcinoma) produced a signaling that lied outside
of the 95% confidence interval. The carcinoma case also
included a prominent reduction of IL-6 receptor function
(Fig. 6), which resulted in an overall cytokine response
pattern comparable to that of the NCI H125 tumor cell
line (Fig. 1A). The changes in signaling reactions corre-
lated with receptor expression. The expression of LIFRα in
normal cells was undetectable by immunoblotting
whereas expression was observed in the 5 cultures of
abnormal cells with LIF response.
The re-expression of LIFR in various cell types is control-
led by an epigenetic process that depends on histone
acetylation within CpG islands of the LIFR promoter
region [22]. To determine whether altered protein acetyla-
tion could account for the switch in LIF responsiveness
from normal to carcinoma cells, the normal epithelial
cells were treated for 6 h with the histone deacetylase
inhibitor FR901228. The treatment induced the expres-
sion of LIFRα and established a LIF-dependent STAT3 and
ERK signaling that was comparable to the level observed
in the carcinoma cells (Fig. 6). A similar FR901228 treat-
ment of the carcinoma cells further enhanced LIFR expres-
sion and LIF-dependent signaling (Fig. 6). Interestingly,
the same treatment reduced he expression of IL-6R in nor-
mal cells resulting in a response pattern as found in the
corresponding carcinoma cells from the same patient (Fig.
6).
Cytokine-specific signalling in bronchial epithelial cells Figure 3
Cytokine-specific signalling in bronchial epithelial 
cells. Paired primary cultures of normal and metaplastic epi-
thelial cells (EC-14) were treated for 15 min with the factors 
listed at the bottom. The relative levels of phosphorylated 
STAT1, STAT3, EGFR and ERK, as well as the total STAT3 
and ERK, were determined by immunoblotting.BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
Page 9 of 16
(page number not for citation purposes)
Activation of STAT1, STAT3 and ERK signalling in paired epithelial cell cultures Figure 4
Activation of STAT1, STAT3 and ERK signalling in paired epithelial cell cultures. Paired cultures of epithelial cells, 
as listed in Table 2, were analyzed for the relative changes in STAT1, STAT2 and ERK signalling mediated by the treatments 
listed at the bottom. The level of phosphorylation of the signalling proteins was expressed relative to the level determined in 
the OSM-treated normal epithelial cells in the corresponding pair of cultures (defined as 100). A, C and E represent 20 pairs 
of the combination normal/normal and B, D and E, represent 23 pairs of the combination of normal/abnormal (metaplasia, dys-
plasia, carcinoma). G and H, indicate the fold-changes in the level of phosphorylated ERK and STAT3 in the matched of culture 
pairs of normal/normal (left side panel) and normal/abnormal epithelial cells. The values for the 4 carcinoma cases are shown 
by open circles.
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Deregulated ERK signalling in metaplastic epithelial cells Figure 5
Deregulated ERK signalling in metaplastic epithelial cells. A. Paired cultures of epithelial cells (EC-85) were analyzed 
by immunoblotting for cytokine-mediated phosphorylation of STAT1, STAT3 and ERK. Basal level of phosphorylated ERK but 
not of phosphorylated STATs is elevated. B, Expression of EGFR, STAT3 and ERK in the untreated cultures was determined by 
immunoblotting. C, Cultures of normal and metaplastic cells were treated for 3 h with serum-free RPMI containing 0.1% car-
rier DMSO or the same medium with 10 µM U0126. The level of phosphorylated ERK was determined by immunoblotting. D, 
DNA synthesis was determined in response to treatment with serially diluted OSM and conditioned medium of LPS activated 
macrophages. One set of cultures of normal and metaplastic cells were also treated for 3 hour with 10 µM U0126 in normal 
growth medium prior to the addition of [3H]thymidine. The incorporation of [3H]thymidine (mean and range of duplicate cul-
tures) were normalized to the number of cells and expressed relative to the values determined for the control cultures of the 
normal epithelial cells.BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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OSM and secreted macrophage factors attenuate 
proliferation of bronchial epithelial cells
DNA synthesis of the epithelial cells was inhibited by
OSM and LPS conditioned medium from of activated
macrophages in a dose-dependent fashion (Fig. 7). The
data for all cultures identified as normal cells (Fig. 7A)
indicated that low concentrations of OSM (≤ 0.1 ng/ml)
or LPS conditioned macrophage medium (<10-3 dilution)
had no appreciable modulating effects. Only at higher
concentrations, suppression of DNA synthesis became
evident (p < 0.05). In contrast, several cultures of meta-
plastic and dysplastic cells exhibited the trend, in which
the cells responded to low doses of OSM or conditioned
medium from macrophages by a stimulation of DNA syn-
thesis (Fig. 7B). The exact sign test using the paired sam-
ples (normal and abnormal) indicated a significant
increase of DNA synthesis by low dose (10-3 dilution) of
macrophage medium (p = 0.016). The comparison of the
data from paired cultures by the Wilcoxon two-sample
test also indicated that DNA synthesis in the abnormal
epithelial cells was significantly increased at lowest con-
centration of OSM (p = 0.02) and macrophage medium (p
= 0.005) relative to the normal cells. The reduced sensitiv-
ity for inhibited DNA synthesis in all cases could be corre-
lated with metaplasia which shows enhanced ERK
phosphorylation in response to cytokine treatment
(example of dysplastic cells in Fig. 7C). In addition, we
noted that in premalignant cells the basal ERK phosphor-
ylation approached the level of OSM-treated cells or EGF-
treated cells (Fig. 4B). In addition, the thymidine incorpo-
ration by premalignant cells maintained in growth
medium was close to two-fold higher than in the corre-
sponding normal cultures (Fig. 5D). As expected, the ERK
activity was reduced by treatment in both normal and car-
cinoma cells with U0126 which correlates with the sup-
pression of DNA synthesis observed (Fig. 5C). High
concentrations of OSM or macrophage factors were effec-
tive to reduce this intrinsically stimulated DNA synthesis
in both normal and premalignant epithelial cell cultures.
Discussion
This study addressed the relationship of inflammation
and oncogenic transformation of lung epithelial cells. We
sought to identify cellular changes in IL-6 cytokine signal-
ing that correlate with attenuated growth suppression of
lung cancer cells. To our knowledge, this is the first report
of a functional comparison of cytokine response in short-
term primary epithelial cell cultures generated from
brushings of normal and abnormal bronchial epithelial
sites as characterized by autofluorescence bronchoscopy.
We were able to demonstrate for the first time that (a) the
response profile of normal epithelial cells and is variable
among individuals, and that (b) premalignant epithelial
cells already have stable changes in receptor activities for
IL-6 cytokines and in signal transduction involving the
ERK pathway. Similar changes in the signaling reactions
are found in established lung cancer cell lines and these
correlate in part with less inhibited cell proliferation.
The interpretation of the results requires the understand-
ing of three underlying issues: (i) the use of primary cell
cultures to define the regulatory phenotypes of cells that
are representative of premalignant lesion in situ; (ii) the
potential mechanism that alters signalling reactions; and
(iii) the causal relationship of altered signaling with the
pattern of gene expression and growth regulation in
abnormal lung cells.
Primary cultures of bronchial epithelial cells as 
representative of specific lesions
Our hypothesis was that the responsiveness of premalig-
nant epithelial cells to inflammatory mediators and IL-6
cytokines is altered and that these changes permit sus-
Regulated expression of LIFR Figure 6
Regulated expression of LIFR. Paired cultures of normal 
and carcinoma cells (EC-9) were incubated with or without 
20 nM FR901228 for 6 h and then treated for 15 min with 
the factors listed at the bottom. The level of phosphorylated 
and total STAT3 and ERK and total LIFRα were determined 
by immunoblotting.BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
Page 12 of 16
(page number not for citation purposes)
tained proliferation in the presence of inflammation. The
target of our functional analyses was the proliferating pre-
malignant cells of the central epithelium, in patients who
had not yet developed lung cancer. All of the patients have
a history of smoking, resulting in the presence of tar dep-
osition and corresponding accumulation of tissue macro-
phages that harbor the ingested tar particles. We used
short-term cultures of proliferating epithelial cells derived
from foci of premalignant change as identified by autoflu-
orescence bronchoscopy.
Our goal was to culture abnormal proliferating cells that
were representative of a specific lesion identified in the
airway with autofluorescence. A tissue sample collected by
a focal biopsy provides lesion-specific cellular material for
culture, which contains an admixture of epithelial cells,
basal cells, fibroblasts and stromal cells [24]. In our col-
lection process, the brush moves across the lesion, collect-
ing a site-specific sample of abnormal cells devoid of non-
epithelial cells. When taken as a whole, the cultured cells
from the foci of premalignancy in the airway behaved dif-
ferently than cultured cells from a normal area in the same
patient. Our functional analyses (Figs. 3,4,5,6,7) indi-
cated a consistent cytokine response pattern, which has
been used as a marker for the phenotype of normal bron-
chial epithelial cells. The quantitative range of responses
observed among preparations likely reflects the individual
variation of epithelial cells due to genetic and cellular dif-
ferentiation differences. We believe that bronchial brush-
ings are optimal for recovering relatively homogenous
cultures of proliferating epithelial cells free of macro-
phages and stromal cells.
As noted above, the cultures of cells obtained from the
brushing of abnormal sites may include cells in different
stages of transformation as well as some normal epithelial
cells. We did find that the relative recovery and growth
rate of viable cells from brushings of normal epithelium
and from pre-malignant epithelial lesions were compara-
ble in vitro. It is conceivable however that normal cells, if
included in the brushing of abnormal sites, could outper-
form the transformed cell types. An experimental assess-
ment of homogeneity included SKY analysis. In all
instances, cells from normal, metaplastic and dysplastic
sites proved to be diploid, which is consistent with the
findings of Franklin et al. [24]. Since we can not rule out
a fractional contribution of normal epithelial cells to the
response profile determined for abnormal cells (Fig.
4B,D,F,G and 4H) the results may underestimate the
altered phenotype of transformed cells.
We know that regulatory phenotypes may have been
influenced by cellular changes introduced by growth ex
vivo, and this creates an unavoidable ambiguity of the tis-
sue culture approach. To normalize for this possibility,
the comparison of normal and abnormal cells adhered to
a strict side-by-side analysis of cultures, which had been
generated and maintained under identical conditions.
The differences discovered by this approach are consid-
ered to describe the effect of the transformation process
on cytokines responsiveness (Fig. 4G and 4H) as well as
proliferation (Fig. 7).
The sites for brushings representing normal and abnormal
epithelium were solely selected based on the visual
appearance when viewed during bronchoscopy, under
two illumination conditions. For each of the 96 patients,
the pathological examination of the sample taken from
normal sites confirmed the normal phenotype of the epi-
thelium. In contrast, the examination of the tissue from
sites with grossly abnormal fluorescence suggested that
only ~50% of the cases involved metaplasia or worse. Epi-
thelial cell cultures from areas of abnormal fluorescence
that did not exhibit preneoplasia under histological exam-
ination normal represented functionally normal epithe-
lium, despite occasional microscopic evidence of
inflammation. The patterns of cytokine signaling and pro-
liferation observed for those cultures were fully compati-
ble with the normal epithelial phenotype (Fig. 4G &4H).
It is conceivable that the causes for the abnormal appear-
ance of the epithelial sites involved transient processes in
the bronchial environment. But the deviation of such sites
from normal epithelium with an altered phenotype could
not be detected in vivo with our analytical tools. The man-
ifestation of these processes could be lost during the estab-
lishment of primary cell cultures.
Mechanisms of altered responsiveness
In the tissue culture amplification of cells from brushings,
the regulatory phenotype represents a stable feature. The
epithelial cell responsiveness to cytokines is subject to
effective positive and negative feedback mechanisms that
could significantly alter the receptor-mediated signaling,
depending on cytokine exposure. Reduction of signaling
by IL-6 cytokines has been associated with treatment-
induced receptor protein down regulation [16,25], expres-
sion of signal modifying SOCS proteins [26] or desensiti-
zation of gp130 [27]. Enhanced signalling can be the
consequence of treatment-induced expression of receptor
proteins [16]. All of these reversible regulatory events are
presumed to be resolved during in vitro culture period
required to establish the primary cells cultures. Treatment
of the cells at this point should provide the most accurate
reflection of the signaling capability of the cytokine recep-
tor systems and the effect on gene expression and prolifer-
ation.
The difference between normal and preneoplastic cell
types goes beyond the range of differences observed for
duplicate samplings of normal epithelium (Fig. 4), and isBMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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Effect of OSM and macrophage factors on DNA synthesis of normal and abnormal epithelial cells Figure 7
Effect of OSM and macrophage factors on DNA synthesis of normal and abnormal epithelial cells. A, Normal 
epithelial cells (25 cultures) and B abnormal epithelial cells (8 metaplasia and 2 dysplasia) were treated with serially diluted 
OSM or conditioned macrophage medium and the incorporation of [3H]thymidine determined. All values expressed relative to 
the untreated cultures in each series. C, Paired cultures of normal and dysplastic epithelial cells (EC-65) were analyzed by 
immunoblotting for OSM-stimulated ERK phosphorylation and the same cells for inhibition of [3H]thymidine incorporation by 
OSM and macrophage-factors (mean and range of duplicate values)BMC Cancer 2005, 5:145 http://www.biomedcentral.com/1471-2407/5/145
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ascribed to the stable modification brought about by the
transformation process. Possible mechanisms are genetic
and epigenetic changes [1,28] that lead to the inactivation
of receptor genes such as silencing LIFR by DNA methyla-
tion [29] or enhanced expression of LIFR, OSMR, but
reduced expression of IL-6R by acetylation of histone and
transcription-controlling factors [22]. Whether enhanced
signaling through LIFR or IL-6R is also a consequence of
gene amplification as noted to be the case for EGFR [30],
is not known. Thus far, no example of a duplication of the
LIFR gene in transformed cells has been reported.
Aside of altered receptor expression, changes in any of the
downstream signal-transducing proteins and enzymes are
likely to contribute to the signaling phenotype of the lung
cells. For instance, no STAT3 signaling by IL-6 cytokine
receptors is found in the prostate PC3 cells because these
cells have lost the genes for STAT3 and STAT5 [31]. None
of the primary cultures or lung cancer cell lines revealed
such a drastic modification of signaling as a function of
transformation. A more common observation in lung can-
cer is the enhanced signaling by IL-6 cytokine receptors
towards the STAT and ERK pathway (Figs. 1,3,4,5). While
immunoblot analysis did not indicate appreciable
changes in the expression levels of these signal-transduc-
ing proteins to account for enhanced signaling, further
work is needed to investigate two other possible mecha-
nisms. First, enhanced signaling might result from altered
level of protein kinases (JAKs, MAPKs), which determine
the engagement of the signaling pathways, and secondly,
it is possible that phosphatase levels might determine the
extent and duration of STAT and MAPK signaling process
[14,32].
The constitutive activation of the ERK pathway as well as
the enhanced signaling through ERK by both IL-6
cytokines and EGF is the most notable feature in about
one quarter of the metaplastic and carcinoma lesions (Fig.
4B &4G). This phenotype, including its U0126 inhibition,
points to an aberration of the MAPK pathway that may
involve the more commonly found oncogenic mutation
of Ras [33]. Alternatively, as already suggested above, a
reduced dephosphorylation of ERK by a deficiency in
appropriate MAPK phosphatase activities could be
involved. These possibilities remain to be identified in
cells derived from premalignant lesions.
Altered cytokine receptor signaling as cause for changed 
cellular response
The profile of gene expression and cellular proliferation
are downstream events from the altered signaling by IL-6
cytokines in premalignant epithelial cells. The deregula-
tion of ERK and enhanced proliferation of epithelial cells
has been noted in many cancer cell types [23,34], and ERK
deregulation appears to also cause the reduced suppres-
sion by OSM and inflammatory cytokines (Fig. 5D &7).
The mode of action may be twofold: enhancing expres-
sion of mitogenic functions (e.g., immediate growth
response genes) and the reduced expression of cell cycle
arresting proteins (p21 and p27) [14,35]. The precise
mode of OSM mediated growth suppression is still
unclear. It has been proposed that enhanced STAT3 activ-
ity is oncogenic [36]. However, a mutant gp130 that is
unable to activate STAT3 also fails to suppress of prolifer-
ation, suggesting STAT3 is a potential inhibitor of growth
[37]. Studies on OSM action on different breast cancer cell
lines cytokines have suggested that the balance between
STAT and ERK activation (magnitude and duration) deter-
mines growth promotion or growth inhibition [37].
Conclusion
Short-term cultures of bronchial epithelial cells can be
established from brushings obtained at bronchoscopy.
Analyses of paired cultures of cells derived from normal
and abnormal site permits the identification of the
responsiveness of the cells to inflammatory mediators.
Normal epithelial cells show a highly consistent and
strong signaling response to OSM, IL-6, and IFNγ and
EGF. Early stage of premalignant transformation is associ-
ated with modified activities of signal transduction path-
ways activated by cytokines. Most prominent alterations
include elevated ERK phosphorylation and re-expression
and function of LIF receptor. OSM and the factors released
by activated pulmonary macrophages suppress prolifera-
tion of normal epithelial cells. However, this suppression
is significantly reduced in abnormal cells. These cytokine
responses in cultured preneoplastic cells are remarkably
similar to those seen in established lung cancer cell lines.
The data suggest that a change in the signaling reaction to
inflammatory mediators as a function of transformation
contributes to the capability of lung tumor cells to prolif-
erate in presence of tumor-associated inflammation.
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